ArticleAntimicrobial agents and chemotherapy2009
Immunity to the bacteriocin sublancin 168 Is determined by the SunI (YolF) protein of Bacillus subtilis.
Article in Antimicrobial agents and chemotherapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 55 citations in OpenAlex.
- Disruption of bacteriophage integration site promotes rapid diversification of multicellular traits inMicrobiology spectrum · 2026Article
- Immunomodulatory properties ofFrontiers in immunology · 2024Article
- Genomic and metabolic insights into the first host-associated isolate ofMicrobiology spectrum · 2023Article
- Gradients in gene essentiality reshape antibacterial research.FEMS microbiology reviews · 2022Review
- Article
- The Antimicrobial Activity of the Glycocin Sublancin Is Dependent on an Active Phosphoenolpyruvate-Sugar Phosphotransferase System.ACS infectious diseases · 2021Article
- The life cycle of SPβ and related phages.Archives of virology · 2021Review
- Extracellular vesicles: An emerging platform in gram-positive bacteria.Microbial cell (Graz, Austria) · 2020Review
- Heterologous biosynthesis and characterization of a glycocin from a thermophilic bacterium.Nature communications · 2019Article
- Differential expression of a prophage-encoded glycocin and its immunity protein suggests a mutualistic strategy of a phage and its host.Scientific reports · 2019Article
- Overview of the Antimicrobial Compounds Produced by Members of theFrontiers in microbiology · 2019Review
- Structure-Activity Relationships of the S-Linked Glycocin Sublancin.ACS chemical biology · 2017Article
- De novo evolved interference competition promotes the spread of biofilm defectors.Nature communications · 2017Article
- Secretome of IntestinalFrontiers in microbiology · 2017Review
- The phosphoenolpyruvate:sugar phosphotransferase system is involved in sensitivity to the glucosylated bacteriocin sublancin.Antimicrobial agents and chemotherapy · 2015Article
- Through the wall: extracellular vesicles in Gram-positive bacteria, mycobacteria and fungi.Nature reviews. Microbiology · 2015Review
- Improved production of sublancin via introduction of three characteristic promoters into operon clusters responsible for this novel distinct glycopeptide biosynthesis.Microbial cell factories · 2015Article
- Extracellular vesicles produced by the Gram-positive bacterium Bacillus subtilis are disrupted by the lipopeptide surfactin.Molecular microbiology · 2014Article
- Co-factor insertion and disulfide bond requirements for twin-arginine translocase-dependent export of the Bacillus subtilis Rieske protein QcrA.The Journal of biological chemistry · 2014Article
- NMR structure of the S-linked glycopeptide sublancin 168.ACS chemical biology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacillus subtilis strain 168 produces the extremely stable lantibiotic sublancin 168, which has a broad spectrum of bactericidal activity. Both sublancin 168 production and producer immunity are determined by the SPbeta prophage. While the sunA and sunT genes for sublancin 168 production have been known for several years, the genetic basis for sublancin 168 producer immunity has remained elusive. Therefore, the present studies were aimed at identifying an SPbeta gene(s) for sublancin 168 immunity. By systematic deletion analysis, we were able to pinpoint one gene, named yolF, as the sublancin 168 producer immunity gene. Growth inhibition assays performed using plates and liquid cultures revealed that YolF is both required and sufficient for sublancin 168 immunity even when heterologously produced in the sublancin-sensitive bacterium Staphylococcus aureus. Accordingly, we propose to rename yolF to sunI (for sublancin immunity). Subcellular localization studies indicate that the SunI protein is anchored to the membrane with a single N-terminal membrane-spanning domain that has an N(out)-C(in) topology. Thus, the bulk of the protein faces the cytoplasm of B. subtilis. This topology has not yet been reported for known bacteriocin producer immunity proteins, which implies that SunI belongs to a novel class of bacteriocin antagonists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.